↓ Skip to main content

Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease

Overview of attention for article published in Frontiers in Pharmacology, February 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease
Published in
Frontiers in Pharmacology, February 2022
DOI 10.3389/fphar.2022.839640
Pubmed ID
Authors

Xueliang Wang, Zhe Wang, Di Liu, Hao Jiang, Chao Cai, Guoyun Li, Guangli Yu

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 21%
Unspecified 1 7%
Student > Bachelor 1 7%
Student > Doctoral Student 1 7%
Student > Master 1 7%
Other 1 7%
Unknown 6 43%
Readers by discipline Count As %
Medicine and Dentistry 4 29%
Biochemistry, Genetics and Molecular Biology 1 7%
Unspecified 1 7%
Unknown 8 57%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2022.
All research outputs
#18,832,709
of 23,339,727 outputs
Outputs from Frontiers in Pharmacology
#8,626
of 16,798 outputs
Outputs of similar age
#318,636
of 442,230 outputs
Outputs of similar age from Frontiers in Pharmacology
#644
of 1,313 outputs
Altmetric has tracked 23,339,727 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,798 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,230 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,313 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.